The advisory brief available discusses four key pillars life sciences executives can leverage to achieve positive outcomes for patients:
- Shape the disease ecosystem and referral pathways to ensure patients are identified, diagnosed and entered into the treatment funnel.
- Invest in patient identification strategies and tactics, such as claims analysis using artificial intelligence and machine learning (AIML), to find and target the right patients for clinical trials and future treatments.
- Develop ways to interact with patients, showing a commitment to their disease by elevating the patient voice and empowering patient communities.
- Offer tailored and customized patient support services (PSS) based on deep patient insights to smooth the patient experience from diagnosis through ongoing treatment and management.
“Rare disease brands face challenges that are different from mainstream therapies and have to find new ways of working to achieve positive outcomes,” explained Jennifer Parr, Partner and Head of Patient Centricity at Trinity Life Sciences. “Strategies and tactics need to be adapted to each disease to evolve the current patient journey and direct resource allocation in the most impactful ways.”
Challenges and solutions regarding each of the four pillars are discussed in a new advisory brief, entitled Calibrating a Patient-centric Approach in Rare Disease: Four Pillars to Focus Resource Allocation. By focusing on the strategies and tactics outlined in the advisory brief, manufacturers in the rare disease space can:
- Help shape the rare disease ecosystem by ensuring patients and Health Care Professionals (HCPs) have the latest information.
- Ensure HCPs are using a data-driven approach to find, appropriately diagnose and provide appropriate care for patients.
- Highlight an ongoing commitment to patients and elevate their profile as patient-centered organizations and leaders.